Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries-Reference-Cited by-同舟云学术

Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries

Published:2021-07-03 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Boeke Caroline E¹,Hiebert Lindsey²,Waked Imam³,Tsertsvadze Tengiz⁴,Sharvadze Lali⁵,Butsashvili Maia⁶,Zakalashvili Mamuka⁷,Naing Win⁸,Gupta Neil⁹,Kateera Fredrick⁹,McClure Craig¹,Ward John W²,Ramers Christian B¹

Affiliation:

1. Clinton Health Access Initiative, Boston, Massachusetts, USA

2. Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, Georgia, USA

3. Hepatology Department, National Liver Institute, Menoufia University, Shebeen El Kom, Egypt

4. Infectious Diseases, AIDS, and Clinical Immunology Research Center, Tbilisi, Georgia

5. Hepatology Clinic Hepa, Tbilisi, Georgia

6. Clinic Neolab, Tbilisi, Georgia

7. Clinic Mrcheveii, Tbilisi, Georgia

8. Yangon Speciality Hospital, Yangon, Myanmar

9. Partners in Health/ Inshuti Mu Buzima, Kigali, Rwanda

Abstract

Abstract Access to recommended second-line treatments is limited for patients who fail initial hepatitis C virus (HCV) therapy in low- and middle-income countries. Alternative regimens and associated outcomes are not well understood. Through a pooled analysis of national program data in Egypt, Georgia, and Myanmar, we observed SVR rates >90% for alternative retreatment regimens.

Funder

United Kingdom Foreign, Commonwealth and Development Office

Coalition for Global Hepatitis Elimination

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab461/39022750/ciab461.pdf

Reference15 articles.

1. Direct acting antivirals failure: cause and retreatment options;Parlati;Expert Rev Gastroenterol Hepatol,2018

2. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection;Bourlière;N Engl J Med,2017

3. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA;Chhatwal;Aliment Pharmacol Ther,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of 8-Week Daclatasvir-Sofosbuvir Regimen in Chronic Hepatitis C: A Systematic Review and Meta-Analysis;2024-09-12

2. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions;The Lancet Gastroenterology & Hepatology;2024-04

3. Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial;The Lancet Gastroenterology & Hepatology;2022-06